{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:34:56Z","timestamp":1794332096887,"version":"4.9.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review outlines the development of the axial spondyloarthritis disease activity score (ASDAS) as a composite index to assess disease activity in axial spondyloarthritis (axSpA) and guide treatment decisions. Our review describes the iterative process by which the ASDAS was validated and its cut off values and improvement scores developed. We compare the ASDAS to the Bath ankylosing spondylitis disease activity index (BASDAI) as a tool for measuring disease activity in axSpA and how its better measurement properties have led to its widespread use in clinical and research settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent international guidelines have recommended the use of the ASDAS as a tool for measuring and monitoring disease activity. ASAS has changed the nomenclature so that ASDAS is based on CRP values whereas ASDAS-ESR retains its original meaning. The BASDAI can be employed as an alternative tool when using the ASDAS is not possible. The ASDAS now forms an important outcome measure in clinical trials and aiming for ASDAS remission has been shown to retard radiographic progression in axSpA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The ASDAS demonstrates improved measurement properties, including greater validity and sensitivity to change, compared to single item variables. It offers a unified metric that enables healthcare professionals to collaborate and communicate more effectively about disease activity and treatment response to interventions in axSpA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001100","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:00:10Z","timestamp":1747803610000},"page":"327-333","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Evolution of the axial spondyloarthritis disease activity score and uptake in clinical practice"],"prefix":"10.1097","volume":"37","author":[{"given":"Saad","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Broomfield Hospital, Mid and South Essex NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London"},{"name":"NIHR University College London Hospitals Biomedical Research Centre"},{"name":"Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2024.20917","article-title":"Axial spondyloarthritis: a review","volume":"333","author":"Bittar","year":"2025","journal-title":"JAMA"},{"key":"R2-20250728","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"R4-20250728","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/annrheumdis-2012-202976","article-title":"Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme","volume":"73","author":"Fern\u00e1ndez-Espartero","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R8-20250728","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/ard.2005.042630","article-title":"An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis","volume":"65","author":"Pham","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/annrheumdis-2015-208274","article-title":"Measurements, composite scores and the art of \u2018cutting-off\u2018","volume":"75","author":"Machado","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","article-title":"Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients","volume":"80","author":"Godfrin-Valnet","year":"2013","journal-title":"Joint Bone Spine"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with nonradiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","article-title":"Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor ( inhibitors","volume":"69","author":"Pedersen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1756-185X.2010.01537.x","article-title":"Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis","volume":"13","author":"Nas","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u200ayears on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R26-20250728","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1093\/rheumatology\/keaa527","article-title":"Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis","volume":"59","author":"Ortolan","year":"2020","journal-title":"Rheumatology"},{"key":"R27-20250728","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","article-title":"Instrument selection for the ASAS core outcome set for axial spondyloarthritis","volume":"82","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R28-20250728","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","article-title":"Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"19","author":"Bautista-Molano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R29-20250728","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbspin.2019.07.007","article-title":"Performance of the ankylosing spondylitis disease activity score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis","volume":"87","author":"Proft","year":"2020","journal-title":"Joint Bone Spine"},{"key":"R31-20250728","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keaa564","article-title":"Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors","volume":"60","author":"Sepriano","year":"2021","journal-title":"Rheumatology"},{"key":"R32-20250728","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R33-20250728","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R34-20250728","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R35-20250728","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R37-20250728","doi-asserted-by":"crossref","first-page":"e001145","DOI":"10.1136\/rmdopen-2019-001145","article-title":"Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI","volume":"6","author":"Marona","year":"2020","journal-title":"RMD Open"},{"key":"R38-20250728","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/rheumatology\/kes057","article-title":"Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria","volume":"51","author":"Fagerli","year":"2012","journal-title":"Rheumatology"},{"key":"R39-20250728","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10067-012-2056-7","article-title":"A simplified version of ankylosing spondylitis disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"31","author":"Sommerfleck","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R40-20250728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-014-0129-9","article-title":"Construct validity and responsiveness of the simplified version of ankylosing spondylitis disease activity score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis","volume":"12","author":"Salaffi","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"R43-20250728","first-page":"752","article-title":"Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis","volume":"28","author":"Aydin","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R44-20250728","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R45-20250728","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kead634","article-title":"Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice","volume":"64","author":"Webers","year":"2025","journal-title":"Rheumatology"},{"key":"R46-20250728","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/kew223","article-title":"BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics","volume":"56","author":"Hamilton","year":"2017","journal-title":"Rheumatology"},{"key":"R49-20250728","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4078\/jrd.2023.0025","article-title":"Korean treatment recommendations for patients with axial spondyloarthritis","volume":"30","author":"Seo","year":"2023","journal-title":"J Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:00:39Z","timestamp":1753722039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001100","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}